Search results
Showing 1 to 15 of 18 results for haemolytic anaemia
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)
Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]
Awaiting development Reference number: GID-TA11855 Expected publication date: TBC
Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)
Evidence-based recommendations on iptacopan (Fabhalta) for treating paroxysmal nocturnal haemoglobinuria in adults.
Show all sections
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]
Awaiting development Reference number: GID-TA11892 Expected publication date: TBC
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.
Evidence-based recommendations on percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve. This involves passing a closure device through a catheter to block the area that is leaking.
View recommendations for HTG585Show all sections
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)
Evidence-based recommendations on fludarabine monotherapy for untreated chronic lymphocytic leukaemia in adults.
NICE has developed a medtech innovation briefing (MIB) on Helge for detecting haemolysis .
High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .
Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)
NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.